Obinutuzumab compared with steroid treatment for adults with minimal change disease
Compares obinutuzumab with glucocorticoids in adults newly diagnosed with minimal change disease.
Key facts
- Who runs it
- Medical University Innsbruck
- Where
- Austria, France, and Germany6 sites in 3 countriesChoose a country to see its sites
- Trial code
- Registry title
- A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD)
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 48 people, planned
- Started
- 13 Jul 2026
- Expected to end
- 30 Jun 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Obinutuzumab Injection
- Predniso(lo)ne
- Record updated
- 17 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a first episode of minimal change disease (MCD), a kidney disease that causes heavy protein loss in urine. It compares obinutuzumab with glucocorticoids.
- Age
- 18 years or older
- Sex
- Male and female
- Disease stage
- First episode of nephrotic syndrome from new (de novo) MCD, confirmed by kidney biopsy. Serum albumin <30g/l and UPCR >3g/g creatinine (>300 mg/mmol).
- Earlier treatment
- No Predniso(lo)ne during screening. No B cell depleting treatment within 18 months (or 12 months if B cells have returned). No cyclophosphamide within 6 months.
- Biomarker or test result
- Serum albumin <30g/l and UPCR >3g/g creatinine (>300 mg/mmol). Women who could become pregnant need a negative pregnancy test.
Main reasons for not taking part
- MCD caused by another illness, such as certain cancers, or by drugs like lithium, interferon or NSAIDs
- Current or past hepatitis B, C or HIV infection, unless preventive treatment is given and no active virus is found
- Severe infection needing treatment within 14 days, or severe heart failure (NYHA class III or IV)
- Cancer within the past 5 years, with some exceptions
- Pregnant or breast-feeding women, or a live vaccine in the 4 weeks before screening
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Understands and agrees to comply with the study procedures and provides informed consent as documented by signature
- Male or female patients aged 18 years or older at the time of consent
- Confirmed first episode of nephrotic syndrome at trial enrolment (serum albumin <30g/l and UPCR >3g/g creatinine (>300 mg/mmol) secondary to de novo MCD
- Histologically confirmed MCD (latest before randomization to Arm A or B)
- Only applies to women of childbearing potential (WOCBP):; Has a high sensitivity negative urine/serum pregnancy test at screening; Agrees to follow contraceptive guidance until 18 months after 2nd obinutuzumab treatment (if randomized to Arm B)
- Only applies to trial sites in France: Patients affiliated with the French health care system
Who cannot take part
- Family history of MCD or in a first degree relative unless previously shown to be steroid-responsive
- Previous cyclophosphamide within 6 months preceding baseline of the trial
- Treatment with Predniso(lo)ne within screening phase (before randomization)
- Evidence of active severe infection requiring systemic antibacterial, antifungal or antiviral therapy within 14 days prior to first dose of study drug
- Live vaccine administration in the four weeks prior to screening and during the study duration of 52 weeks
- Previous/known hypersensitivity to predniso(lo)ne or obinutuzumab or to any of the excipients to be in accordance with the SmPC of Gazyvaro
- MCD due to secondary causes, including malignancy of a type likely to be associated with MCD (i.e., lymphoproliferative disorders), or potentially related to treatment known to be associated with MCD occurrence (lithium, interferon, non-steroidal anti-inflammatory drugs)
- Evidence of current or past infection with Hepatitis B, C or Human Immunodeficiency Virus (HIV) (unless appropriate prophylaxis is given and no replicating virus is detected)
- Severe heart failure or severe, uncontrolled cardiac disease (NYHA class III or IV)
- Patient with a history of prior malignancy within 5 years before the first dose of study drug. Exceptions may apply for the following: malignancies with a negligible risk of metastasis or death such as adequately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, ductal carcinoma in situ, or Stage I uterine cancer
- Previous B cell depletion, independent of the agent and treatment target (i.e., CD20, CD38, etc.), within 18 months preceding baseline of the trial, or 12 months if there is evidence of B cell return in peripheral lymphocyte subsets
- Pregnant or breast-feeding women
- Co-enrolment in another clinical trial of an investigational medicinal product
- Any other reason which, in the opinion of the Principal Investigator (PI), renders the patient unsuitable for the trial
This trial has no sites in United States.
It has sites in 3 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
OBELIX-NEPHROSIS (NS)
Read full original descriptionShow less
The goal of this clinical trial is to learn if obinutuzumab works to treat minimal change disease in adults. It will also learn about the safety of drug obinutuzumab. The main questions it aims to answer are:
Is obinutuzumab non-inferior to glucocorticoids at inducing remission? Does obinutuzumab provide superiority in terms of relapse-free survival after 52 weeks? What medical problems do participants have when receiving obinutuzumab? Researchers will compare drug obinutuzumab to glucocorticoids and aim to phenotype participants with minimal change disease.
Participants will:
Take the drug obinutuzumab (2 doses) or glucocorticoids Visit the clinic for 8 visits over a period of 52 weeks, plus additional controls when disease relapses occur
The 2 groups in the trial
- ObinutuzumabTreatment being tested
Treatment: Obinutuzumab Injection
- GlucocorticoidsExisting treatment, for comparison
Treatment: Predniso(lo)ne
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Randomized Controlled, Two-arm (1:1 Ratio) Phase IIa Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With de Novo Minimal Change Disease
- Plain-language title
- Obinutuzumab compared with steroid treatment for adults with minimal change diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 17 August 2026